IRIS
PAOLICELLI, DAMIANO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.275
AS - Asia 3.529
EU - Europa 3.099
SA - Sud America 974
AF - Africa 265
Continente sconosciuto - Info sul continente non disponibili 9
OC - Oceania 9
Totale 16.160
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.110
SG - Singapore 1.367
IT - Italia 1.115
CN - Cina 807
BR - Brasile 760
HK - Hong Kong 461
RU - Federazione Russa 395
SE - Svezia 385
VN - Vietnam 302
DE - Germania 248
FR - Francia 223
GB - Regno Unito 194
FI - Finlandia 164
UA - Ucraina 119
IN - India 110
CI - Costa d'Avorio 109
BD - Bangladesh 96
CA - Canada 81
AR - Argentina 79
ID - Indonesia 62
NL - Olanda 56
JP - Giappone 53
ZA - Sudafrica 44
IQ - Iraq 43
MX - Messico 42
BE - Belgio 41
PK - Pakistan 37
TR - Turchia 34
VE - Venezuela 33
CO - Colombia 29
EC - Ecuador 29
ES - Italia 27
PL - Polonia 27
SA - Arabia Saudita 26
AT - Austria 23
TN - Tunisia 22
PH - Filippine 21
UZ - Uzbekistan 19
MA - Marocco 18
CL - Cile 15
RO - Romania 14
EG - Egitto 13
JO - Giordania 11
KE - Kenya 11
JM - Giamaica 10
LT - Lituania 10
AE - Emirati Arabi Uniti 9
PY - Paraguay 9
UY - Uruguay 9
AU - Australia 8
CZ - Repubblica Ceca 8
ET - Etiopia 8
MY - Malesia 8
OM - Oman 8
AZ - Azerbaigian 7
CR - Costa Rica 7
DZ - Algeria 7
IR - Iran 7
KZ - Kazakistan 7
NP - Nepal 7
PA - Panama 7
SN - Senegal 7
AL - Albania 6
DO - Repubblica Dominicana 6
IE - Irlanda 6
PE - Perù 6
BG - Bulgaria 5
BO - Bolivia 5
KG - Kirghizistan 5
PS - Palestinian Territory 5
PT - Portogallo 5
CH - Svizzera 4
EU - Europa 4
HU - Ungheria 4
IL - Israele 4
NG - Nigeria 4
DK - Danimarca 3
GR - Grecia 3
HR - Croazia 3
SC - Seychelles 3
A1 - Anonimo 2
AO - Angola 2
BB - Barbados 2
BS - Bahamas 2
HN - Honduras 2
KR - Corea 2
LB - Libano 2
MK - Macedonia 2
MZ - Mozambico 2
PR - Porto Rico 2
RS - Serbia 2
RW - Ruanda 2
TH - Thailandia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
BF - Burkina Faso 1
BH - Bahrain 1
BJ - Benin 1
CG - Congo 1
EE - Estonia 1
GA - Gabon 1
Totale 16.132
Salva come PNG Salva come JPEG
Città #
Fairfield 893
Ashburn 849
Singapore 726
Woodbridge 603
Chandler 514
Hong Kong 461
San Jose 455
Houston 428
Seattle 402
Milan 367
Cambridge 315
Wilmington 307
Nyköping 290
Beijing 261
Jacksonville 226
Ann Arbor 224
Dallas 177
New York 141
Lauterbourg 139
Los Angeles 119
Bari 118
Lawrence 118
Rome 114
Roxbury 114
Abidjan 109
Boardman 95
Ho Chi Minh City 95
Nanjing 94
Helsinki 75
Des Moines 73
Princeton 68
Santa Clara 65
Brooklyn 61
Columbus 58
Council Bluffs 58
Buffalo 55
Munich 55
São Paulo 55
Chicago 52
Hanoi 51
Tokyo 51
Inglewood 49
London 43
Brussels 40
Moscow 40
San Diego 39
Frankfurt am Main 37
Jakarta 36
Orem 35
Falkenstein 34
Nuremberg 33
Toronto 29
Rio de Janeiro 28
Turin 26
Montreal 25
Nanchang 25
Atlanta 24
Figino 24
Shenyang 24
Amsterdam 23
Guangzhou 22
Johannesburg 22
Norwalk 21
San Francisco 21
Warsaw 21
Belo Horizonte 20
Dong Ket 20
Phoenix 20
Baghdad 18
Denver 18
Tianjin 18
Chennai 17
Hebei 17
Jiaxing 17
Paris 17
Shanghai 15
Stockholm 15
Haiphong 14
Lahore 14
Poplar 14
Tashkent 14
Bisceglie 13
Boston 13
Caracas 13
Dhaka 13
Brasília 12
Buenos Aires 12
Marseille 12
North Bergen 12
Salt Lake City 12
Wuhan 12
Cagliari 11
Da Nang 11
Manchester 11
Mexico City 11
Palermo 11
Changsha 10
Jeddah 10
Medellín 10
Miami 10
Totale 10.739
Salva come PNG Salva come JPEG
Nome #
Long-term cardiac safety and tolerability of fingolimod in multiple sclerosis: A postmarketing study 231
Signs and symptoms of COVID-19 in patients with multiple sclerosis 221
RELATIONSHIP OF COGNITIVE PERFORMANCES AND EMPLOYMENT STATUS IN PEOPLE WITH RELAPSING MULTIPLE SCLEROSIS 211
Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis 205
Prognostic indicators in pediatric clinically isolated syndrome 190
The Cost of Patients With Relapsing-Remitting Multiple Sclerosis Who Develop Neutralizing Antibodies While Treated With Interferon Beta 188
Age-related changes of serum N-acetyl-aspartate in healthy controls. 187
A rare association between multiple sclerosis and Charcot-Marie-Tooth type 1B 187
Gender differences in safety issues during Fingolimod therapy: Evidence from a real-life Relapsing Multiple Sclerosis cohort 185
Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategies 183
Adhesion molecules and matrix metalloproteinases in Multiple Sclerosis: effects induced by Interferon-beta 182
Lymphocyte subsets as biomarkers of therapeutic response in Fingolimod treated Relapsing Multiple Sclerosis patients 180
"Better explanations" in multiple sclerosis diagnostic workup: A 3-year longitudinal study 171
Retrospectively acquired cohort study to evaluate the long-term impact of two different treatment strategies on disability outcomes in patients with relapsing multiple sclerosis (RE.LO.DI.MS): data from the Italian MS Register 171
Age-related disability in multiple sclerosis 168
Long-Term Data of Efficacy, Safety, and Tolerability in a Real-Life Setting of THC/CBD Oromucosal Spray-Treated Multiple Sclerosis Patients 166
Lymphocyte count and body mass index as biomarkers of early treatment response in a multiple sclerosis dimethyl fumarate-treated cohort 163
The cost of relapsing-remitting multiple sclerosis patients who develop neutralizing antibodies during interferon beta therapy 162
Associations between cognitive impairment at onset and disability accrual in young people with multiple sclerosis 157
Exploratory analysis of predictors of patient adherence to subcutaneous interferon beta-1a in multiple sclerosis: TRACER study 151
Impact of natalizumab on cognitive performances and fatigue in relapsing multiple sclerosis: a prospective, open-label, two years observational study. 150
Cerebrospinal fluid neurofilament light levels mark grey matter volume in clinically isolated syndrome suggestive of multiple sclerosis 150
Analisi longitudinale dei livelli sierici di ICAM-1 solubile e dei subsets di linfociti T in pazienti con Sclerosi Multipla a decorso remittente in trattamento con IFNb-1b 147
BLOOD MMP-9 AND SICAM-1 AS MARKERS OF RIFN-B TREATMENT EFFICACY IN RELAPSING-REMITTING MS 145
PBMC of Multiple Sclerosis Patients Show Deregulation of OPA1 Processing Associated with Increased ROS and PHB2 Protein Levels 143
Predictors of long-term disability accrual in relapse-onset multiple sclerosis 139
Seroconversion and indolent course of COVID-19 in patients with multiple sclerosis treated with fingolimod and teriflunomide 137
Multiple Sclerosis Progression and Relapse Activity in Children 136
Mitoxantrone prior to interferon beta-1b in aggressive relapsing multiple sclerosis: a 3-year randomised trial. 134
Atypical forms of Multiple Sclerosis or different phases of a same disease? 131
A multicenter, observational, prospective study of self- and parent-reported quality of life in adolescent multiple sclerosis patients self-administering interferon-β1a using RebiSmart™-the FUTURE study. 129
Cost-Effectiveness Analysis of Cannabinoid Oromucosal Spray Use for the Management of Spasticity in Subjects with Multiple Sclerosis 128
Long-term comparative analysis of no evidence of disease activity (NEDA-3) status between multiple sclerosis patients treated with natalizumab and fingolimod for up to 4 years 128
Review of interferon beta-1b in the treatment of early and relapsing multiple sclerosis. 127
DMTs and Covid-19 severity in MS: a pooled analysis from Italy and France 126
Sativex in resistant multiple sclerosis spasticity: Discontinuation study in a large population of Italian patients (SA.FE. study) 126
Efficacy and Safety of Oral Therapies for Relapsing-Remitting Multiple Sclerosis 125
Patient expression of emotions and neurologist responses in first multiple sclerosis consultations 123
ADHESION MOLECULES AND MATRIX METALLOPROTEINASES IN MS: EFFECTS INDUCED BY INTERFERON BETA 122
Longitudinal Evaluation of Serum MOG-IgG and AQP4-IgG Antibodies in NMOSD by a Semiquantitative Ratiometric Method 122
The frequency of CSF oligoclonal banding in multiple sclerosis increases with latitude. 121
COVID-19 Severity in Multiple Sclerosis: Putting Data Into Context 121
Real-Life Experience of the Effects of Cladribine Tablets on Lymphocyte Subsets and Serum Neurofilament Light Chain Levels in Relapsing Multiple Sclerosis Patients 120
The role of neutralizing antibodies to interferon-β as a biomarker of persistent MRI activity in multiple sclerosis: a 7-year observational study 120
Geographical variations in sex ratio trends over time in multiple sclerosis. 119
Breastfeeding is not related to postpartum relapses in multiple sclerosis. 119
Neuromyelitis optica spectrum disorders associated with systemic sclerosis: a case report and literature review 118
Early prediction of the long term evolution of multiple sclerosis: the Bayesian Risk Estimate for Multiple Sclerosis (BREMS) score. 117
Low serum urate levels are associated to female gender in multiple sclerosis patients. 117
Magnetoencephalography and high‐density electroencephalography study of acoustic event related potentials in early stage of multiple sclerosis: A pilot study on cognitive impairment and fatigue 117
Predictors of disability worsening in clinically isolated syndrome 116
Effect of cladribine on neuronal apoptosis: New insight of in vitro study in multiple sclerosis therapy 116
Predictors of unemployment status in people with relapsing multiple sclerosis: a single center experience 116
Durvalumab and multiple sclerosis: a causal link or simple unmasking? 115
PML risk is the main factor driving the choice of discontinuing natalizumab in a large multiple sclerosis population: results from an Italian multicenter retrospective study 115
Lesion load may predict long-term cognitive dysfunction in multiple sclerosis patients 114
A nurse-led, telephone-based patient support program for improving adherence in patients with relapsing-remitting multiple sclerosis using interferon beta-1a: Lessons from a consumer-based survey on adveva® PSP 112
Risk of multiple sclerosis relapses when switching from fingolimod to cell-depleting agents: the role of washout duration 112
Clinical and biological predictors of Cladribine effectiveness in Multiple Sclerosis: A real-world, single Centre study considering a two-year interval from year-2 dosing 109
null 109
Epidural analgesia and cesarean delivery in multiple sclerosis post-partum relapses: the Italian cohort study. 109
Natural history of multiple sclerosis: have available therapies impacted long-term prognosis? 109
Age-related gadolinium-enhancement of MRI brain lesions in multiple sclerosis. 109
Defining the course of tumefactive multiple sclerosis: a large retrospective multicentre study 108
Postmarketing evidence of disease-modifying drugs in multiple sclerosis 106
The transition from relapsing-remitting MS to irreversible disability: clinical evaluation. 103
Guidelines on the clinical use for the detection of neutralizing antibodies (NAbs) to IFN beta in multiple sclerosis therapy: report from the Italian Multiple Sclerosis Study group. 101
Macular ganglion cell-inner plexiform layer defect patterns in multiple sclerosis patients without optic neuritis: A Spectral-Domain-Optical Coherence Tomography Cross-Sectional, Case-Control, Pilot Study 100
CHANGES OF SERUM ICAM-1 AND MMP-9 INDUCED BY RIFNB-1B TREATMENT IN RELAPSING-REMITTING MS 99
Characteristics and treatment of Multiple Sclerosis-related trigeminal neuralgia: An Italian multi-centre study 99
Impact of depression on the perception of fatigue and information processing speed in a cohort of multiple sclerosis patients 98
Variations of the perforin gene in patients with multiple sclerosis. 98
Transition to secondary progression in relapsing-onset multiple sclerosis: Definitions and risk factors 98
A case report of late-onset atypical Hemolytic Uremic Syndrome during interferon beta in multiple sclerosis: Open issues in literature review 96
Coverage of the requirements of first and second level stroke unit in Italy 96
Informing MS patients on treatment options: a consensus on the process of consent taking 93
Interferon beta in relapsing-remitting multiple sclerosis: an independent postmarketing study in southern Italy 92
Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: II: Maternal risks 89
Harmonization of real-world studies in multiple sclerosis: Retrospective analysis from the rirems group 89
Modificazioni dei livelli sierici di ICAM-1 solubile (sICAM.1), e Gelatinasi A e B e sottopopolazioni T-linfocitarie di sangue periferico indotte dal trattamento con interferone-beta-1b (IFN-BETA-1B) in pazienti con Sclerosi Multipla (SM) Relapsing-Remitting (RR): Relazione con la produzione di anticorpi neutralizzanti anti-interferone (NABs) 88
Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks 88
RIFNB DOWNREGULATES TNFA-INDUCED ICAM-1 EXPRESSION ON BRAIN MICROVASCULAR ENDOTHELIAL CELLS (BEMC) AND INCREASES SERUM SOLUBLE ICAM-1 (SICAM-1) IN RR MS 87
CHANGES OF SERUM SOLUBLE ICAM-1 AND MATRIX METALLOPROTEINASE-9 DURING INTERFERON BETA-1B TREATMENT IN RR MS 87
Pregnancy and fetal outcomes after Glatiramer Acetate exposure in patients with multiple sclerosis: a prospective observational multicentric study 87
Clinical and patient determinants of changing therapy in relapsing-remitting multiple sclerosis (SWITCH study) 87
Acoustic Voice Analysis as a Useful Tool to Discriminate Different ALS Phenotypes 87
The differential diagnosis of multiple sclerosis: classification and clinical features of relapsing and progressive neurological syndromes. 86
SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort study 85
The Italian Multiple Sclerosis Database Network (MSDN): the risk of worsening according to IFNbeta exposure in multiple sclerosis. 84
A comparison of natalizumab and ocrelizumab on disease progression in multiple sclerosis 83
Immunomodulatory therapies delay disease progression in multiple sclerosis. 82
A multicenter survey on access to care in Multiple Sclerosis-related trigeminal neuralgia 81
Disability trajectories by progression independent of relapse activity status differ in pediatric, adult and late-onset multiple sclerosis 80
Enhancement is an age-related feature of multiple sclerosis lesions 80
A cross-sectional, multicentre study of the therapeutic management of multiple sclerosis relapses in Italy. 80
Nabiximols discontinuation rate in a large population of patients with multiple sclerosis: A 18-month multicentre study 80
Mitochondria, Oxidative Stress, cAMP Signalling and Apoptosis: A Crossroads in Lymphocytes of Multiple Sclerosis, a Possible Role of Nutraceutics 80
An Internet- and Kinect-Based Multiple Sclerosis Fitness Intervention Training With Pilates Exercises: Development and Usability Study 78
The impact of neutralizing antibodies on the risk of disease worsening in interferon β-treated relapsing multiple sclerosis: a 5 year post-marketing study. 78
Changes of serum sICAM-1 and MMP-9 induced by rIFN beta-1b treatment in relapsing-remitting MS 77
Totale 12.287
Salva come PNG Salva come JPEG
Categoria #
all - tutte 69.781
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 69.781
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022936 57 109 16 33 44 88 43 46 86 59 173 182
2022/20231.382 225 178 83 122 162 162 17 165 204 5 26 33
2023/2024461 57 66 28 29 37 108 13 18 8 23 6 68
2024/20252.782 133 42 180 102 75 246 257 223 133 166 424 801
2025/20266.424 842 357 436 736 652 360 642 213 664 593 222 707
2026/2027193 193 0 0 0 0 0 0 0 0 0 0 0
Totale 16.664